Literature DB >> 7907372

Isolation, structural determination, and biological activity of 6 alpha-hydroxytaxol, the principal human metabolite of taxol.

J W Harris1, A Katki, L W Anderson, G N Chmurny, J V Paukstelis, J M Collins.   

Abstract

The principal biotransformation product of taxol was found to be identical for human hepatic microsomes, human liver slices, and patient bile samples. We have isolated this metabolite from the bile of a patient given taxol, and we report its structure and its cytotoxicity relative to taxol. The NMR and SIMS data presented here indicate that, in humans, taxol is regiospecifically hydroxylated at the 6-position on the taxane ring and that this hydroxyl is stereospecifically placed trans to the hydroxyl at position 7, yielding 6 alpha-hydroxytaxol. This metabolite is apparently not formed in rats. Tests of the growth inhibition potential of 6 alpha-hydroxytaxol versus taxol in two human tumor cell lines showed that the metabolite was approximately 30-fold less cytotoxic than taxol. Thus the cytochrome P-450-mediated biotransformation of taxol to 6 alpha-hydroxytaxol can be classified as a detoxification reaction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7907372     DOI: 10.1021/jm00031a022

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

Review 1.  Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors:  Bertrand Rochat
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Lung cancer in HIV Infection.

Authors:  Deepthi Mani; Missak Haigentz; David M Aboulafia
Journal:  Clin Lung Cancer       Date:  2011-07-29       Impact factor: 4.785

Review 3.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.

Authors:  K T Kivistö; H K Kroemer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

5.  Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.

Authors:  Milly E de Jonge; Alwin Dr Huitema; Jan Hm Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

6.  Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences.

Authors:  C A Jamis-Dow; R W Klecker; A G Katki; J M Collins
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alpha-hydroxytaxol.

Authors:  G Kumar; S Ray; T Walle; Y Huang; M Willingham; S Self; K Bhalla
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Extensive and saturable accumulation of paclitaxel by the human platelet.

Authors:  M D Wild; U K Walle; T Walle
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants.

Authors:  Radka Václavíková; Stanislav Horský; Petr Simek; Ivan Gut
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-08-14       Impact factor: 3.000

10.  Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.

Authors:  A Sparreboom; M T Huizing; J J Boesen; W J Nooijen; O van Tellingen; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.